Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Hypertriglyceridemia
Interventions
DRUG

ISIS apoC-III Rx

Dose 1

DRUG

ISIS apoC-III Rx

Dose 2

DRUG

ISIS apoC-III Rx

Dose 3

DRUG

Placebo

Dose 1

DRUG

Placebo

Dose 2

DRUG

Placebo

Dose 3

Trial Locations (7)

27828

Farmville Internal Medicine, Farmville

27834

Mark R. Cervi, Greenville

Physicians East, Quadrangle Medical Specialists, Greenville

27858

Carolina East Family Medicine, Greenville

27893

Natalie A Doyle, MD PA, Wilson

28504

Eastern Carolina Physicians, Kinston

Unknown

Isis Investigational site, Chicoutimi

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY

NCT01529424 - Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia | Biotech Hunter | Biotech Hunter